Exagen Inc. develops and markets various test products based on its Cell-Bound Complement Activation Products technology under the AVISE brand name in the United States. The company is headquartered in Vista, California.
| Revenue (TTM) | $71.12M |
| Gross Profit (TTM) | $41.70M |
| EBITDA | $-10.77M |
| Operating Margin | -8.64% |
| Return on Equity | -113.80% |
| Return on Assets | -14.90% |
| Revenue/Share (TTM) | $3.01 |
| Book Value | $0.51 |
| Price-to-Book | 13.21 |
| Price-to-Sales (TTM) | 2.28 |
| EV/Revenue | 2.289 |
| EV/EBITDA | -0.16 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 15.90% |
| Shares Outstanding | $24.23M |
| Float | $13.87M |
| % Insiders | 27.83% |
| % Institutions | 44.88% |
Volatility is currently expanding
Exagen NASDAQ: XGN reported record second-quarter revenue as growth in AVISE CTD test volume, average selling price and Pharma Services revenue brought the autoimmune diagnostics company close to adjusted EBITDA break-even.
Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript
Exagen Inc. (XGN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.18 per share a year ago.
Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 - $75 million CARLSBAD, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2026, and recent corporate updates.
CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor conference: Canaccord Genuity 46 th Annual Growth Conference – Boston, MA Date: August 11, 2026Fireside Chat at 8:30am ETA live and archived webcast of the Fireside Chat will be available on Exagen's Investor Relations website at investors.exagen.com.
CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026, before the market opens on Tuesday, August 4, 2026.
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive diagnosis Performed consistently across more than 1,200 SLE patients and 14 medical centers, expanding on the original clinical validation CARLSBAD, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the publication of a new systematic review demonstrating that the AVISE Lupus algorithm delivers markedly superior diagnostic accuracy and consistency across patient populations compared with conventional serologic tests alone.
The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Exagen (XGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen NASDAQ: XGN reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician adoption helped offset a weather-related disruption early in the quarter.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on XGN and any ticker you trade — then tracks every position and per-strategy win rate.
